Skip to main content
NCBI home page
Journal of Clinical Laboratory Analysis logoLink to Journal of Clinical Laboratory Analysis
. 2002 Sep 27;16(5):253–258. doi: 10.1002/jcla.10051

MPS screening methods, the berry spot and acid turbidity tests, cause a high incidence of false‐negative results in sanfilippo and morquio syndromes

Chang Chih‐Kuang 1,✉, Lin Shuan‐Pei 1,2, Lee Shyue‐Jye 3, Wang Tuen‐Jen 3
PMCID: PMC6808023  PMID: 12357455

Abstract

Because of differences in the types and quantities of glycosaminoglycans (GAGs) in various mucopolysaccharidoses (MPSs), MPS screening tests, including the Berry spot and acid turbidity tests, are not specific or sensitive enough for the preliminary diagnosis of MPS. A false‐negative result is common. We analyzed urine samples collected from 492 patients who were examined for inborn errors of metabolism using the Berry spot and acid turbidity (qualitative and quantitative) tests. Of those, 48 MPS patients (seven with MPS I, 17 with MPS II, nine with MPS III, 11 with MPS IV, and four with MPS VI) underwent preliminary differentiation between MPS types by two‐dimensional electrophoresis (2D‐EP), and were confirmed by enzymatic assay. Approximately 21.0% and 7.1% of the 492 samples showed positive reactions in the Berry spot and acid turbidity tests, respectively. Of these, a total of 35 samples with MPS types I, II, and VI showed strong positive reactions in both tests. Five patients with Sanfilippo (MPS III) and six patients with Morquio (IV) syndromes showed false‐negative results in both tests. In our study, approximately 13.8% (68 in 492 samples) samples showed a positive reaction in the Berry spot test but a negative one in the acid turbidity test, for unknown reasons. The Berry spot and acid turbidity tests are used extensively for the preliminary diagnosis of MPS in Asia; however, the possibility of a misdiagnosis of MPS type III and IV with both tests should be kept in mind. For accurate diagnosis and confirmation of MPS, the 2D‐EP method and enzymatic assay are recommended. They provide high sensitivity, specificity, and efficiency in diagnosing MPS. J. Clin. Lab. Anal. 16:253–258, 2002. © 2002 Wiley‐Liss, Inc.

Keywords: glycosaminoglycan, mucopolysaccharidoses, acid turbidity test, Berry spot test, dimethylmethylene blue method, two‐dimensional electrophoresis

REFERENCES

  • 1. Neufeld EF, Muenzer J. The mucopolysaccharidoses In: Scriver CR, Beaudst Al, Sly WS, Valle D. The metabolic and molecular bases of inherited disease. New York: McGraw‐Hill, Inc., Health Profession Division; 1995. p 2465–2494. [Google Scholar]
  • 2. Applegarth DA, Dimmick JE, Hall JG. New York. Organelle diseases: clinical features, diagnosis, pathogenesis and management. London: Chapman & Hall Medical; 1997. p 45–97. [Google Scholar]
  • 3. Besley GTN, Wraith JE. Lysosomal disorders. Curr Paediatri 1997;7:128–134. [Google Scholar]
  • 4. Wraith JE. Mucopolysaccharidoses. Curr Paediatri 1996;6:74–79. [Google Scholar]
  • 5. Berry HK, Spinanger J. A paper spot test useful in study of Hurler's syndrome. J Lab Clin Med 1960;55:136–139. [PubMed] [Google Scholar]
  • 6. Berry HK. Screening for mucopolysaccharide disorders with the Berry spot test. Clin Biochem 1987;20:365–371. [DOI] [PubMed] [Google Scholar]
  • 7. Huang KC, Sukegawa K, Orii T. Screening test for urinary glycosaminoglycans and differentiation of various muco‐polysaccharidoses. Clin Chim Acta 1985;151:147–156. [DOI] [PubMed] [Google Scholar]
  • 8. Rezvani I, Collipp PJ, DiGeoge AM. Evaluation of screening tests for urinary mucopolysaccharides. Pediatrics 1973;52:64–68. [PubMed] [Google Scholar]
  • 9. de Jong JG, Wevers RA, Laarakkers C, Poorthuis BJ. Dimethylmethylene blue‐based spectrophotometry of glycos‐aminoglycans in untreated urine: a rapid screening procedure for mucopolysaccharidoses. Clin Chem 1989;35:1472–1477. [PubMed] [Google Scholar]
  • 10. Hopwood JJ, Harrison JR. High‐resolution electrophoresis of urinary glycosaminoglycans: an improved screening test for the mucopolysaccharidoses. Anal Biochem 1982;119:120–127. [DOI] [PubMed] [Google Scholar]
  • 11. Dembure PP, Roesel RA. Screening for mucopolysaccharidoses by analysis of urinary glycosaminoglycans In: Hommes FA. Techniques in diagnostic human biochemical genetics—a laboratory manual. New York: Wiley‐Liss, Inc.; 1991. p 77–86. [Google Scholar]
  • 12. Berman ER, Vered J, Bach G. A reliable spot test for mucopolysaccharidoses. Clin Chem 1971;17:886–890. [PubMed] [Google Scholar]
  • 13. de Jong JG, Hasselman JJ, van Landeghem AA, Vader HL, Wevers RA. The spot test is not a reliable screening procedure for mucopolysaccharidoses. Clin Chem 1991;37:572–575. [PubMed] [Google Scholar]
  • 14. Brimble A, Pennock C, Stone J. Results of a quality assurance exercise for urinary glycosaminoglycan excretion. Ann Clin Biochem 1990;27:133–138. [DOI] [PubMed] [Google Scholar]
  • 15. Chuang CK, Lin SP, Chung SF. Diagnostic screening for mucopolysaccharidoses by the dimethylmethylene blue method and two dimensional electrophoresis. Chinese Med J (Taipei)(Taipei) 2001;64:15–22. [PubMed] [Google Scholar]
  • 16. Voznyi YV, Keulemans JL, van Diggelen OP. A fluorogenic assay for the diagnosis of Hunter disease (MPS II). J Inher Metab Dis 2001;24:675–680. [DOI] [PubMed] [Google Scholar]
  • 17. Karpova EA, Voznyi YV, Keulemans JL, et al. A fluorimetric enzyme assay for the diagnosis of Sanfilippo disease type A (MPS IIIA). J Inher Metab Dis 1996;19:278–285. [DOI] [PubMed] [Google Scholar]
  • 18. Marsh J, Fensom AH. 4‐Methylumbellifery α‐N‐acetylglucosaminidase activity for diagnosis of Sanfilippo B disease. Clin Genet 1985;27:258–262. [DOI] [PubMed] [Google Scholar]
  • 19. van Diggelen, Zhao H, Kleijer WJ, et al. A fluorimetric enzyme assay for the diagnosis of Morquio disease type A (MPS IVA). Clin Chim Acta 1990;187:131–140. [DOI] [PubMed] [Google Scholar]
  • 20. Carter CH, Wan AT, Carpenter DG. Commonly used tests in the detection of Hurler's syndrome. J Pediatr 1968;73:217–221. [DOI] [PubMed] [Google Scholar]
  • 21. Rattenbury JM, Worthy E, Allen JC. Screening tests for glycosaminoglycans in urine: experience from regional inter‐laboratory surveys. J Clin Pathol 1988;41:936–939. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Mossman J, Patrick AD. Prenatal diagnosis of mucopoly‐saccharidosis by two‐dimensional electrophoresis of amniotic fluid glycosaminoglycans. Prenat Diagn 1982;2:169–176. [DOI] [PubMed] [Google Scholar]
  • 23. Kleijer WJ, Karpova EA, Geilen GC, et al. Prenatal diagnosis of Sanfilippo A syndrome: experience in 35 pregnancies at risk and the use of a new fluorogenic substrate for the heparin sulphamidase assay. Prenat Diagn 1996;16:829–835. [DOI] [PubMed] [Google Scholar]
  • 24. Kleijer WJ, Geilen GC, Garritsen V, et al. First‐trimester diagnosis of Morquio disease type A. Prenat Diagn 2000;20:183–185. [PubMed] [Google Scholar]
  • 25. Li P, Bellows AB, Thompson JN. Molecular basis of iduronate‐2‐sulphatase gene mutations in patients with mucopolysaccharidosis type II (Hunter syndrome). J Med Genet 1999;36:21–27. [PMC free article] [PubMed] [Google Scholar]
  • 26. Vafiadaki E, Cooper A, Heptinstall LE, Hatton CE, Thornley M, Wraith JE. Mutation analysis in 57 unrelated patients with MPS II (Hunter disease). Arch Dis Child 1998;79:237–241. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Laboratory Analysis are provided here courtesy of Wiley

RESOURCES